Published • loading... • Updated
Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia
- Abbisko Therapeutics announced preliminary Phase 2 results for lavengratinib in children aged 6 and older with achondroplasia.
- After 27 weeks, seven participants receiving 0.064 mg/kg once daily had a mean annualized height-velocity increase of 2.4 cm per year from baseline.
- The company reported a 100% responder rate in the lowest-dose cohort.
Insights by Ground AI
39 Articles
39 Articles
Henry Herald+38 Reposted by 38 other sources
Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia
SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- 21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective orally available…
·Georgia, United States
Read Full ArticleCoverage Details
Total News Sources39
Leaning Left5Leaning Right2Center27Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
15%
C 79%
Factuality
To view factuality data please Upgrade to Premium
